

REMARKS

Claims 1-13 have been rewritten as claims 14-24 to conform to US practice. There is no new matter added, and entry of the amendment is respectfully requested.

Applicants enclose a paper copy of a Sequence Listing and a computer-readable form of the Sequence Listing. The content of the paper copy of the Sequence Listing and of the computer readable form is the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: June 29, 2004



Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097